drugset / Trial / NCT07075419
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Penpulimab in patients with hepatocellular carcinoma after standard treatment failure.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2027-07-01
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JDB153 | Unknown | 500 mg | Oral |
| Subject | JDB153 | Unknown | 600 mg | Oral |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |